We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
A venture capital firm made about $470 million on a buzzy biotech's $8 billion acquisition, and has its eye on these promising areas next
United States News News
Aisling Capital managing partner Steve Elms told Business Insider about the other biotechs and scientific areas the firm is intrigued by.